Le Heuzey Jean-Yves, Marijon Eloi, Otmani Akli, Lepillier Antoine, Waintraub Xavier, Lavergne Thomas, Pornin Maurice
Service de Cardiologie A et Rythmologie, Hôpital Européen Georges Pompidou, Université Paris 5, Paris, France.
Therapie. 2009 Mar-Apr;64(2):115-9. doi: 10.2515/therapie/2009011. Epub 2009 Aug 11.
Treatment of patients with both atrial fibrillation and heart failure remains uneasy. In theory maintenance of sinus rhythm is desirable but the only pharmacological intervention able to do it safely is amiodarone. A trial of strategy randomisation, restoration of sinus rhythm or slowing of atrial fibrillation, has been done in patients with both atrial fibrillation and heart failure. This trial, named AF-CHF has shown neutral results, the 2 strategies, rhythm control or simple rate control were similar in terms of mortality. Dronedarone is an innovative drug bringing new possibilities in the treatment of atrial fibrillation but it is contra-indicated in case of severe heart failure. Another possible approach is that of non pharmacological techniques. Sinus rhythm maintenance may be obtained by pulmonary vein isolation. The other possibility is the ablation of atrio-ventricular node with implantation of a pacemaker, technique which is reserved to selected patients.